- Report
- March 2019
- 110 Pages
Global
From €3090EUR$3,250USD£2,596GBP
- Report
- June 2018
- 15 Pages
Global
From €9507EUR$10,000USD£7,986GBP
- Report
- January 2024
- 106 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- October 2022
- 69 Pages
Global
From €3327EUR$3,500USD£2,795GBP
- Report
- September 2022
- 1079 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- May 2022
- 41 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- December 2022
- 42 Pages
Global
From €3327EUR$3,500USD£2,795GBP
- Report
- May 2022
- 36 Pages
Global
From €3327EUR$3,500USD£2,795GBP
- Report
- May 2022
- 207 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- May 2022
- 55 Pages
Global
From €1901EUR$2,000USD£1,597GBP
Dyskinesia is a neurological disorder characterized by involuntary, repetitive movements. It is most commonly associated with the use of certain central nervous system drugs, such as antipsychotics and levodopa. Dyskinesia can cause a range of physical symptoms, including jerky movements, tremors, and difficulty with coordination. It can also lead to psychological symptoms, such as anxiety and depression.
The dyskinesia market is composed of a range of pharmaceutical companies that produce drugs to treat the disorder. These companies develop and market medications that can reduce the severity of symptoms and improve quality of life. Many of these drugs are approved by the FDA and are available in both generic and brand-name forms.
Some of the companies in the dyskinesia market include AbbVie, Allergan, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Teva Pharmaceuticals. Show Less Read more